Tech Company Inital Public Offerings
Monte Rosa Therapeutics IPO
On 6/24/2021, Monte Rosa Therapeutics completed its IPO
Transaction Overview
Company Name
Announced On
6/24/2021
Transaction Type
IPO
Amount
$186,200,000
Proceeds Purpose
Use of proceeds for the Monte Rosa Therapeutics IPO are outlined in the company's S1 filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
40 Guest St.
Boston, MA 02135
USA
Boston, MA 02135
USA
Phone
Undisclosed
Website
Email Address
Overview
Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Markus Warmuth
Chief Financial Officer
Ajim Tamboli
Chief Scientific Officer
John Castle
Chief Scientific Officer
Owen Wallace
Vice President
Silvia Buonamici
Vice President
Alexander Flohr
Vice President
Giorgio Ottaviani
VP - Bus. Development
Jullian Jones
Browse more venture capital transactions:
Prev: 6/24/2021: Adela venture capital transaction
Next: 6/24/2021: Moth+Flame venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs